Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?
Here is how Anika Therapeutics (ANIK) and Concentra Group (CON) have performed compared to their sector so far this year.
Zacks Investment Research9/25/2026Positive
ANIK
Anika Therapeutics IncNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$272.61M
P/E Ratio
—
EPS
$-0.23
Beta
0.20
52W High
$22.88
52W Low
$8.67
50-Day MA
$19.74
200-Day MA
$14.67
Dividend Yield
—
Profit Margin
-3.14%
Forward P/E
21.51
PEG Ratio
2.15
About Anika Therapeutics Inc
Anika Therapeutics, Inc., is a joint preservation company in the United States, Europe, and internationally. The company is headquartered in Bedford, Massachusetts.
Fundamentals
| Revenue (TTM) | $120.65M |
| Gross Profit (TTM) | $75.00M |
| EBITDA | $3.04M |
| Operating Margin | 11.40% |
| Return on Equity | -2.19% |
| Return on Assets | -0.87% |
| Revenue/Share (TTM) | $8.69 |
| Book Value | $10.26 |
| Price-to-Book | 1.99 |
| Price-to-Sales (TTM) | 2.26 |
| EV/Revenue | 2.159 |
| EV/EBITDA | 508.83 |
| Quarterly Earnings Growth (YoY) | -50.50% |
| Quarterly Revenue Growth (YoY) | 15.60% |
| Shares Outstanding | $13.38M |
| Float | $11.29M |
| % Insiders | 6.40% |
| % Institutions | 93.45% |
Historical Volatility
HV 10-Day
19.83%
HV 20-Day
20.80%
HV 30-Day
23.39%
HV 60-Day
47.75%
HV Rank
6.7%
Volatility is currently contracting
Analyst Ratings
Consensus ($22.00 target)
1
Strong Buy1
BuyLatest News
Best Momentum Stocks to Buy for August 26th
BTSG, ANIK and OPHC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 26th, 2026.
Zacks Investment Research8/26/2026Positive
Anika (ANIK) Is a Great Choice for 'Trend' Investors, Here's Why
Anika (ANIK) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Zacks Investment Research8/24/2026Positive
Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?
ANIK's strong sales momentum and raised 2026 guidance bolster investor confidence, while Cingal and Hyalofast advance its pipeline.
Zacks Investment Research8/21/2026Positive
5 Stocks With Recent Price Strength to Enhance Your Portfolio Returns
Five stocks, including EDRY, OPHC, FET, ANIK and NESR, show strong recent price gains and earnings growth as markets rally.
Zacks Investment Research8/19/2026Positive
Anika Therapeutics (ANIK) Is Up 11.10% in One Week: What You Should Know
Does Anika Therapeutics (ANIK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Investment Research8/14/2026Positive
5 Stocks With Recent Price Strength to Tap August Rally
Five stocks, including OPHC, EDRY, ENVA, ANIK and GEO, show strong recent price gains and earnings growth as markets rally.
Zacks Investment Research8/10/2026Positive
Anika (ANIK) is on the Move, Here's Why the Trend Could be Sustainable
Anika (ANIK) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Zacks Investment Research8/7/2026Positive
Anika Therapeutics Q2 Earnings Call Highlights
Anika Therapeutics NASDAQ: ANIK reported higher second-quarter revenue, expanded gross margin and its strongest adjusted EBITDA performance since 2020, as international commercial growth and manufacturing improvements supported profitability.
MarketBeat7/29/2026Positive
Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026
BEDFORD, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its second quarter 2026 financial results before the opening of the market on Wednesday, July 29, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.
GlobeNewsWire7/15/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ANIK and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/26/2026